Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Cut to Strong Sell at DZ Bank

DZ Bank lowered shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a strong-buy rating to a strong sell rating in a report released on Wednesday morning,Zacks.com reports.

BAYRY has been the topic of several other research reports. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Finally, Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Trading Down 3.5%

OTCMKTS BAYRY opened at $12.81 on Wednesday. Bayer Aktiengesellschaft has a one year low of $5.30 and a one year high of $14.85. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71. The firm has a market cap of $50.34 billion, a P/E ratio of -142.32, a P/E/G ratio of 4.76 and a beta of 0.68. The stock’s 50-day moving average is $12.17 and its 200-day moving average is $9.62.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.